FDA Should Amend Irinotecan Label to Reflect That Not All Patients Need Accompanying Dx, Study Says | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration should amend the label of a commonly prescribed cancer drug to reflect that a molecular diagnostic used to predict adverse events in some patients is not required for all patients, according to the findings of a recent meta-analysis.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.